Title : Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

Pub. Date : 2013 Jun

PMID : 23456778






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 PATIENTS AND METHODS: Chinese patients >= 18 years with histologically confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received erlotinib (150 mg/day; n = 82) or gemcitabine-carboplatin (n = 72). gemcitabine epidermal growth factor receptor Homo sapiens